Search Results - "Cohen, Ander"

Two Year Outcome After Chronic Iliac Vein Occlusion Recanalisation Using the Vici Venous Stent by Black, Stephen, Gwozdz, Adam, Karunanithy, Narayan, Silickas, Justinas, Breen, Karen, Hunt, Beverley, Smith, Alberto, Cohen, Ander, Saha, Prakash

“…The aim was to assess two year outcomes with placement of the Vici Venous Stent® in patients with chronic iliofemoral venous occlusions (complete blockage)…”
Get full text

AngioJet Pharmacomechanical Thrombectomy and Catheter Directed Thrombolysis vs. Catheter Directed Thrombolysis Alone for the Treatment of Iliofemoral Deep Vein Thrombosis: A Single Centre Retrospective Cohort Study by Pouncey, Anna L., Gwozdz, Adam M., Johnson, Oscar W., Silickas, Justinas, Saha, Prakash, Thulasidasan, Narayan, Karunanithy, Narayan, Cohen, Ander T., Black, Stephen A.

“…Percutaneous thrombus removal is used for the treatment of iliofemoral deep vein thrombosis (DVT), but the efficacy of different treatment modalities has not…”
Get full text

Idraparinux versus Standard Therapy for Venous Thromboembolic Disease by Buller, Harry R, Cohen, Ander T, Davidson, Bruce, Decousus, Hervé, Gallus, Alex S, Gent, Michael, Pillion, Gerard, Piovella, Franco, Prins, Martin H, Raskob, Gary E

“…The long-acting factor X inhibitor idraparinux was compared with a standard antithrombotic regimen in two randomized trials, one for the treatment of deep…”
Get full text

Machine learning to predict venous thrombosis in acutely ill medical patients by Nafee, Tarek, Gibson, C. Michael, Travis, Ryan, Yee, Megan K., Kerneis, Mathieu, Chi, Gerald, AlKhalfan, Fahad, Hernandez, Adrian F., Hull, Russell D., Cohen, Ander T., Harrington, Robert A., Goldhaber, Samuel Z.

“…The identification of acutely ill patients at high risk for venous thromboembolism (VTE) may be determined clinically or by use of integer‐based scoring…”
Get full text

Extended Prophylaxis of Venous Thromboembolism with Idraparinux by Buller, Harry R, Cohen, Ander T, Davidson, Bruce, Decousus, Hervé, Gallus, Alex S, Gent, Michael, Pillion, Gerard, Piovella, Franco, Prins, Martin H, Raskob, Gary E

“…The high risk of recurrent venous thromboembolism in patients with idiopathic venous thrombosis or pulmonary embolism is reason for extended thromboprophylaxis…”
Get full text

Interview with Alexander Cohen by Cohen, Alexander (Ander)

“…Alexander (Ander) Cohen MBBS (Hons), MSc, MD, FRACP is a vascular physician and epidemiologist at Guy's and St Thomas' Hospital, King's College (London, UK)…”
Get full text

A feasibility study to inform the design of a randomised controlled trial to identify the most clinically effective and cost-effective length of Anticoagulation with Low-molecular-weight heparin In the treatment of Cancer-Associated Thrombosis (ALICAT) by Noble, Simon I, Nelson, Annmarie, Fitzmaurice, David, Bekkers, Marie-Jet, Baillie, Jessica, Sivell, Stephanie, Canham, Joanna, Smith, Joanna D, Casbard, Angela, Cohen, Ander, Cohen, David, Evans, Jessica, Fletcher, Kate, Johnson, Miriam, Maraveyas, Anthony, Prout, Hayley, Hood, Kerenza

“…Venous thromboembolism is common in cancer patients and requires anticoagulation with low-molecular-weight heparin (LMWH). Current data recommend LMWH for…”
Get full text

Direct Oral Anticoagulants and Their Use in Treatment and Secondary Prevention of Acute Symptomatic Venous Thromboembolism by Granziera, Serena, Hasan, Arjumand, Cohen, Alexander Ander T

“…Direct oral anticoagulants (DOACs) have been compared with standard therapy in large phase III studies to assess their safety and efficacy in the treatment of…”
Get more information

NOACs for thromboprophylaxis in medical patients by Cohen, Alexander (Ander) T., MBBS, MSc, MD, FRACP, Rider, Tom, MBBS

“…The risk of venous thrombosis extends for an indeterminate length of time following admission to hospital with a medical or surgical condition. Observational…”
Get full text

New agents for DOAC reversal: a practical management review by White, Katie, Faruqi, Uzma, Cohen, Alexander (Ander) T

“…Bleeding is the commonest and most concerning adverse event associated with anticoagulants. Bleeding, depending on the severity, is managed in various ways,…”
Get full text

d-Dimer elevation and adverse outcomes by Halaby, Rim, Popma, Christopher J., Cohen, Ander, Chi, Gerald, Zacarkim, Marcelo Rodrigues, Romero, Gonzalo, Goldhaber, Samuel Z., Hull, Russell, Hernandez, Adrian, Mentz, Robert, Harrington, Robert, Lip, Gregory, Peacock, Frank, Welker, James, Martin-Loeches, Ignacio, Daaboul, Yazan, Korjian, Serge, Gibson, C. Michael

“…d -Dimer is a biomarker of fibrin formation and degradation. While a d -dimer within normal limits is used to rule out the diagnosis of deep venous thrombosis…”
Get full text

Early Outcomes Following Endoluminal Deep Venous Reconstruction Using Dedicated Venous Stents by Saha, Prakash, Black, Stephen A, Cohen, Ander, Karunanithy, Narayan, Hunt, Beverley J, Breen, Karen

“…Objectives Evaluate early outcomes following endoluminal stenting using first-generation dedicated venous stents. Methods Patients undergoing deep venous…”
Get full text

COMPARISON OF ORAL ANTICOAGULANTS OR ANTIPLATELET THERAPY FOR THE EXTENDED TREATMENT OF VENOUS THROMBOEMBOLISM: SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS by Cohen, Ander, Batson, Sarah, Hamilton, Melissa, Masseria, Cristina, Mitchell, Stephen, Phatak, Hemant

“…Background: A systematic review and network meta-analysis (NMA) were conducted to compare oral anticoagulants and aspirin for the secondary prevention of…”
Get full text

Effect of thrombophilia on clinical outcomes of chronic post-thrombotic patients after iliofemoral stenting with nitinol venous stents by Gwozdz, Adam M., Doyle, Andrew J., Hunt, Beverley J., Tincknell, Laura G., Jackson, Nick, Saha, Prakash, Breen, Karen A., Smith, Alberto, Cohen, Ander, Black, Stephen A.

“…Thrombophilia is a prothrombotic condition that increases the risk of venous thromboembolism. It is unclear whether the presence of thrombophilia alters the…”
Get full text

The Efficacy and Safety of Pharmacological Prophylaxis of VTE Following Elective Knee or Hip Replacement: Systematic Review and Network Meta-Analysis by Cohen, Ander, Pieter, Drost, Marchant, Nick, Mitchell, Stephen, Orme, Michelle, Simon, Teresa, Sutton, Alex, Rublee, Dale

“…Abstract 2314 Venous thromboembolism (VTE) collectively describes the debilitating, painful and potentially fatal conditions of deep vein thrombosis (DVT) and…”
Get full text

Patency Rates After Stenting Across the Inguinal Ligament for Treatment of Post-Thrombotic Syndrome Using Nitinol Venous Stents by Saha, Prakash, PhD, MRCS, Gwozdz, Adam, Hagley, Danny, El-Sayed, Tamer, Hunt, Beverley, McDonald, Vickie, Cohen, Ander, Breen, Karen, Karunanithy, Narayan, Black, Stephen

Get full text

COMPARATIVE EFFECTIVENESS OF APIXABAN VERSUS WARFARIN FOR TREATMENT OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH AND WITHOUT ACTIVE CANCER by Wygant, Gail D., Guo, Jennifer, Rosenblatt, Lisa, Weycker, Derek, Li, Shawn, Lee, Theodore, Luo, Xuemei, Mardekian, Jack, Hanau, Ahuva, Atwood, Mark, Pan, Xianying, Cohen, Alexander (Ander)

Get full text

Abstract 16280: Betrixaban Reduced the Occurrence of Major Adverse Cardiovascular Events Among Acute Medically Ill Patients With a History of Myocardial Infarction or Stroke: Insights From the APEX Trial by Nafee, Tarek O, Gibson, C M, Yee, Megan K, Kerneis, Mathieu, Travis, Ryan, AlKhalfan, Fahad, Chi, Gerald, Hull, Russell D, Hernandez, Adrian F, Cohen, Ander T, Harrington, Robert A, Goldhaber, Samuel Z

“…BackgroundBetrixaban reduced the occurrence of venous thrombosis, compared to enoxaparin, among patients hospitalized for acute medically illness. However,…”
Get full text

PARADOXICAL PROTECTIVE EFFECT OF OBESITY ON THE RISK OF VENOUS THROMBOEMBOLISM: OBSERVATIONS FROM APEX TRIAL by Karabay, Arzu Kalayci, Gibson, C. Michael, Chi, Gerald, Alkhalfan, Fahad, Pitliya, Anmol, Walia, Sargun Singh, Nafee, Tarek, Mir, Mahshid, Kazmi, Syed Hassan Abbas, Qamar, Iqra, Hernandez, Adrian, Hull, Russell, Cohen, Alexander (Ander), Harrington, Robert, Goldhaber, Samuel

Get full text

HOSPITALIZATIONS, RECURRENT VENOUS THROMBOEMBOLISM OR VENOUS THROMBOEMBOLISM-RELATED DEATH, AND MAJOR BLEEDING, BY INDEX EVENT FROM THE AMPLIFY TRIAL by Lee, Theodore, Masseria, Cristina, Breazna, Andrei, DiRusso, Gregory, Hamilton, Melissa, Horblyuk, Ruslan, Mardekian, Jack, Porcari, Anthony, Cohen, Alexander (Ander)

“…Background In AMPLIFY six months of oral apixaban was non-inferior to enoxaparin followed by warfarin (enox/warf) in reducing the rate of recurrent venous…”
Get full text